The aryl hydrocarbon receptor links integrin signaling to the TGF-β pathway

Oncogene

Volumn 35, Issue 25, 2016, Pages 3260-3271

  Silginer, M ^a   Burghardt, I ^a   Gramatzki, D ^a   Bunse, L ^b   Leske, H ^c   Rushing, E J ^c   Hao, N ^d   Platten, M ^b   Weller, M ^a   Roth, P ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; BETA3 INTEGRIN; BETA5 INTEGRIN; CD51 ANTIGEN; CILENGITIDE; INTEGRIN; MESSENGER RNA; NEUTRALIZING ANTIBODY; NUCLEAR PROTEIN; RNA; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; CYCLIC ARGININE-GLYCINE-ASPARTIC ACID PEPTIDE; CYCLOPEPTIDE; GLPG0187; NAPHTHYRIDINE DERIVATIVE; SNAKE VENOM; SULFONAMIDE;

ARTICLE; ASTROCYTE; CELL DENSITY; CONTROLLED STUDY; GENE EXPRESSION; GENE SILENCING; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIVER CELL; PRIORITY JOURNAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN TUMOR; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; GENETICS; GLIOBLASTOMA; IMMUNOBLOTTING; KNOCKOUT MOUSE; METABOLISM; NEWBORN; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, NEUTRALIZING; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELLS, CULTURED; GLIOBLASTOMA; HEPATOCYTES; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTEGRINS; MICE, INBRED C57BL; MICE, KNOCKOUT; NAPHTHYRIDINES; PEPTIDES, CYCLIC; RECEPTORS, ARYL HYDROCARBON; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SNAKE VENOMS; SULFONAMIDES; TRANSFORMING GROWTH FACTOR BETA;

EID: 84975769676     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.387     Document Type: Article

References (49)

1. Denison MS, Rogers JM, Rushing SR, Jones CL, Tetangco SC, Heath-Pagliuso S. Analysis of the aryl hydrocarbon receptor (AhR) signal transduction pathway. Curr Protoc Toxicol 2002, Chapter 4:Unit4.8.
2. Nguyen LP, Bradfield CA. The search for endogenous activators of the aryl hydrocarbon receptor. Chem Res Toxicol 2008; 21: 102-116.
3. Stockinger B, Di Meglio P, Gialitakis M, Duarte JH. The aryl hydrocarbon receptor: multitasking in the immune system. Annu Rev Immunol 2014; 32: 403-432.
4. Dietrich C, Kaina B. The aryl hydrocarbon receptor (AhR) in the regulation of cell-cell contact and tumor growth. Carcinogenesis 2010; 31: 1319-1328.
5. Feng S, Cao Z, Wang X. Role of aryl hydrocarbon receptor in cancer. Biochim Biophys Acta 2013; 1836: 197-210.
6. Safe S, Lee SO, Jin UH. Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target. Toxicol Sci 2013; 135: 1-16.
7. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011; 478: 197-203.
8. Gramatzki D, Pantazis G, Schittenhelm J, Tabatabai G, Kohle C, Wick W et al. Aryl hydrocarbon receptor inhibition downregulates the TGF-beta/Smad pathway in human glioblastoma cells. Oncogene 2009; 28: 2593-2605.
9. Joseph JV, Balasubramaniyan V, Walenkamp A, Kruyt FA. TGF-beta as a therapeutic target in high grade gliomas - promises and challenges. Biochem Pharmacol 2013; 85: 478-485.
10. Seoane J, Le HV, Shen L, Anderson SA, Massague J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 2004; 117: 211-223.
11. Roth P, Silginer M, Goodman SL, Hasenbach K, Thies S, Maurer G et al. Integrin control of the transforming growth factor-beta pathway in glioblastoma. Brain 2013; 136(Pt 2): 564-576.
12. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10: 9-22.
13. Kung T, Murphy KA, White LA. The aryl hydrocarbon receptor (AhR) pathway as a regulatory pathway for cell adhesion and matrix metabolism. Biochem Pharmacol 2009; 77: 536-546.
14. Juan SH, Lee JL, Ho PY, Lee YH, Lee WS. Antiproliferative and antiangiogenic effects of 3-methylcholanthrene, an aryl-hydrocarbon receptor agonist, in human umbilical vascular endothelial cells. Eur J Pharmacol 2006; 530: 1-8.
15. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 2004; 279: 23847-23850.
16. Maurer GD, Tritschler I, Adams B, Tabatabai G, Wick W, Stupp R et al. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro Oncol 2009; 11: 747-756.
17. Murray IA, Reen RK, Leathery N, Ramadoss P, Bonati L, Gonzalez FJ et al. Evidence that ligand binding is a key determinant of Ah receptor-mediated transcriptional activity. Arch Biochem Biophys 2005; 442: 59-71.
18. Silginer M, Weller M, Ziegler U, Roth P. Integrin inhibition promotes atypical anoikis in glioma cells. Cell Death Dis 2014; 5: e1012.
19. Bruna A, Darken RS, Rojo F, Ocana A, Penuelas S, Arias et al. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 2007; 11: 147-160.
20. Prell RA, Kerkvliet NI. Involvement of altered B7 expression in dioxin immunotoxicity: B7 transfection restores the CTL but not the autoantibody response to the P815 mastocytoma. J Immunol 1997; 158: 2695-2703.
21. Riecke K, Schmidt A, Stahlmann R. Effects of 2,3,7,8-TCDD and PCB 126 on human thymic epithelial cells in vitro. Arch Toxicol 2003; 77: 358-364.
22. Monteiro P, Gilot D, Le Ferrec E, Lecureur V, N'Diaye M, Le Vee M et al. AhR- and c-maf-dependent induction of beta7-integrin expression in human macrophages in response to environmental polycyclic aromatic hydrocarbons. Biochem Biophys Res Commun 2007; 358: 442-448.
23. Abe Y, Sinozaki H, Takagi T, Minegishi T, Kokame K, Kangawa K et al. Identification of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-inducible genes in human amniotic epithelial cells. Reprod Biol Endocrinol 2006; 4: 27.
24. Mulero-Navarro S, Pozo-Guisado E, Perez-Mancera PA, Alvarez-Barrientos A, Catalina-Fernandez I, Hernandez-Nieto E et al. Immortalized mouse mammary fibroblasts lacking dioxin receptor have impaired tumorigenicity in a subcutaneous mouse xenograft model. J Biol Chem 2005; 280: 28731-28741.
25. Sadek CM, Allen-Hoffmann BL. Suspension-mediated induction of Hepa 1c1c7 Cyp1a-1 expression is dependent on the Ah receptor signal transduction pathway. J Biol Chem 1994; 269: 31505-31509.
26. Sadek CM, Allen-Hoffmann BL. Cytochrome P450IA1 is rapidly induced in normal human keratinocytes in the absence of xenobiotics. J Biol Chem 1994; 269: 16067-16074.
27. Ikuta T, Kobayashi Y, Kawajiri K. Cell density regulates intracellular localization of aryl hydrocarbon receptor. J Biol Chem 2004; 279: 19209-19216.
28. Cho YC, Zheng W, Jefcoate CR. Disruption of cell-cell contact maximally but transiently activates AhR-mediated transcription in 10T1/2 fibroblasts. Toxicol Appl Pharmacol 2004; 199: 220-238.
29. Mimura J, Ema M, Sogawa K, Fujii-Kuriyama Y. Identification of a novel mechanism of regulation of Ah (dioxin) receptor function. Genes Dev 1999; 13: 20-25.
30. Davarinos NA, Pollenz RS. Aryl hydrocarbon receptor imported into the nucleus following ligand binding is rapidly degraded via the cytosplasmic proteasome following nuclear export. J Biol Chem 1999; 274: 28708-28715.
31. Dohr O, Sinning R, Vogel C, Munzel P, Abel J. Effect of transforming growth factor-beta1 on expression of aryl hydrocarbon receptor and genes of Ah gene battery: clues for independent down-regulation in A549 cells. Mol Pharmacol 1997; 51: 703-710.
32. Wolff S, Harper PA, Wong JM, Mostert V, Wang Y, Abel J. Cell-specific regulation of human aryl hydrocarbon receptor expression by transforming growth factor-beta (1). Mol Pharmacol 2001; 59: 716-724.
33. Gaido KW, Maness SC, Leonard LS, Greenlee WF. 2,3,7,8-Tetrachlorodibenzo-pdioxin-dependent regulation of transforming growth factors-alpha and -beta 2 expression in a human keratinocyte cell line involves both transcriptional and post-transcriptional control. J Biol Chem 1992; 267: 24591-24595.
34. Vogel C, Abel J. Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on growth factor expression in the human breast cancer cell line MCF-7. Arch Toxicol 1995; 69: 259-265.
35. Corchero J, Martin-Partido G, Dallas SL, Fernandez-Salguero PM. Liver portal fibrosis in dioxin receptor-null mice that overexpress the latent transforming growth factor-beta-binding protein-1. Int J Exp Pathol 2004; 85: 295-302.
36. Santiago-Josefat B, Mulero-Navarro S, Dallas SL, Fernandez-Salguero PM. Overexpression of latent transforming growth factor-beta binding protein 1 (LTBP-1) in dioxin receptor-null mouse embryo fibroblasts. J Cell Sci 2004; 117(Pt 6): 849-859.
37. Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1100-1108.
38. Rodon J, Carducci M, Sepulveda-Sanchez JM, Azaro A, Calvo E, Seoane J et al. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-beta receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Invest New Drugs 2014; 33: 357-370.
39. Codo P, Weller M, Meister G, Szabo E, Steinle A, Wolter M et al. Micro RNA mediated down-regulation of NKG2D ligands contributes to glioma immune escape. Oncotarget 2014; 5: 7651-7662.
40. Hao N, Lee KL, Furness SG, Bosdotter C, Poellinger L, Whitelaw ML. Xenobiotics and loss of cell adhesion drive distinct transcriptional outcomes by aryl hydrocarbon receptor signaling. Mol Pharmacol 2012; 82: 1082-1093.
41. Townsend D, Witkop CJ Jr., Mattson J. Tyrosinase subcellular distribution and kinetic parameters in wild type and C-locus mutant C57BL/6J mice. J Exp Zool 1981; 216: 113-119.
42. Carraro G, Albertin G, Forneris M, Nussdorfer GG. Similar sequence-free amplification of human glyceraldehyde-3-phosphate dehydrogenase for real time RT-PCR applications. Mol Cell Probes 2005; 19: 181-186.
43. Kress S, Reichert J, Schwarz M. Functional analysis of the human cytochrome P4501A1 (CYP1A1) gene enhancer. Eur J Biochem 1998; 258: 803-812.
44. Mason GG, Witte AM, Whitelaw ML, Antonsson C, McGuire J, Wilhelmsson et al. Purification of the DNA binding form of dioxin receptor. Role of the Arnt cofactor in regulation of dioxin receptor function. J Biol Chem 1994; 269: 4438-4449.
45. Wirsching HG, Krishnan S, Florea AM, Frei K, Krayenbuhl N, Hasenbach K et al. Thymosin beta 4 gene silencing decreases stemness and invasiveness in glioblastoma. Brain 2014; 137(Pt 2): 433-448.
46. Goodman SL, Grote HJ, Wilm C. Matched rabbit monoclonal antibodies against alphav-series integrins reveal a novel alphavbeta3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors. Biol Open 2012; 1: 329-340.
47. Frei K, Gramatzki D, Tritschler I, Schroeder JJ, Espinoza L, Rushing EJ et al. Transforming growth factor-beta pathway activity in glioblastoma. Oncotarget 2015; 6: 5963-5977.
48. Kraus JA, Dabbs DJ, Beriwal S, Bhargava R. Semi-quantitative immunohistochemical assay versus oncotype DX((R)) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study. Mod Pathol 2012; 25: 869-876.
49. Kinsel LB, Szabo E, Greene GL, Konrath J, Leight GS, McCarty KS Jr.. Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. Cancer Res 1989; 49: 1052-1056.